systems and methods to confirm safe delivery of treatment energy to a patient by identifying a presence of a fault in an energy delivery pathway and identifying a location of the fault within the device. The system includes a processing unit configured to calculate blood impedances external to the device based on known impedance characteristics of the device, and then to calculate impedances within the device during energy delivery based on the calculated blood impedances. The processing unit prevents the delivery of energy in an energy delivery pathway that is determined to be compromised. The processing unit is also configured to compare times for two different frequencies to travel a predetermined distance, the difference in the times corresponding to a location of a fault within the energy delivery pathway.
|
1. A system for assessing integrity of an energy delivery pathway, the system comprising:
an energy generator including a processing unit;
an electrode distribution system in communication with the energy generator;
an impedance measuring device in communication with the electrode distribution system;
a medical device in communication with the electrode distribution system including an elongate body having a proximal portion, a distal portion, and a lumen extending between the proximal portion and the distal portion, a treatment element at the distal portion having at least one electrode, and at least two electrode wires in electrical communication with the at least one electrode, the energy delivery pathway including at least a part of each of the at least two electrode wires,
the energy generator being configured to deliver a first current at a first frequency and a second current at a second frequency to the at least one electrode, the impedance measuring device being configured to:
before a delivery of treatment energy from the energy generator, identify a first wire impedance within the device elongate body, a second wire impedance within the device elongate body, and a first shunt admittance within the device elongate body;
during the delivery of the first current at the first frequency and the second current at the second frequency, calculate a first blood impedance external to the device elongate body, a second blood impedance external to the device elongate body, and a blood admittance external to the device elongate body based on the determined first wire impedance within the elongate body, the determined second wire impedance within the device elongate body, and the first shunt admittance within the elongate body;
during the delivery of the first current at the first frequency and the second current at the second frequency, calculate a third wire impedance within the device elongate body, a fourth wire impedance within the device elongate body, and a second shunt admittance within the device elongate body based on the first blood impedance external to the device elongate body, the second blood impedance external to the device elongate body, and the blood admittance external to the device elongate body; and
at least one of:
compare the calculated third wire impedance within the device elongate body and the calculated fourth wire impedance within the device elongate body to determine if a fault in the energy delivery pathway exists; and
compare the second shunt admittance within the device elongate body to a threshold blood admittance value to determine if a fault in the energy delivery pathway exists.
2. The system of
3. The system of
4. The system of
5. The system of
6. The system of
applying a first condition, i1≠0, i2≠0, to the equations:
where V1 is the known voltage of the first voltage source, V2 is the known voltage of the second voltage source, R1 is the known resistance of the first electrode wire, R2 is the known resistance of the second electrode wire, Zl,1 is the known series impedance of the first electrode wire, Zl,2 is the known series impedance of the second electrode wire, and Ysh is the sum of a blood admittance within the elongate body of the device (Yl,1-2) and the blood admittance external to the elongate body (Yb,1-2); and
applying a second condition, i′1≠0, i′2=0, to the equations:
where V′1 is the known voltage of the first voltage source, R1 is the known resistance of the first electrode wire, and Zl,1 is the known series impedance of the first electrode wire.
7. The system of
applying the first condition, i1≠0, i2≠0, to the equations:
where V1 is the known voltage of the first voltage source, V2 is the known voltage of the second voltage source, R1 is the known resistance of the first electrode wire, R2 is the known resistance of the second electrode wire, Zl,1 is the known series impedance of the first electrode wire, Zl,2 is the known series impedance of the second electrode wire, and Ysh is the sum of a blood admittance within the elongate body of the device (Yl,1-2) and the blood admittance external to the elongate body (Yb,1-2); and
applying the second condition, i′1≠0, i′2=0, to the equations:
|
n/a
n/a
This disclosure relates to a method and system for confirming safe energy delivery during an ablation or treatment procedure and for identifying of a location of potential short or open circuit within an ablation or treatment device.
Cardiac arrhythmias disrupt normal heart rhythm and cardiac efficiency. These arrhythmias can be treated using, for example, pulsed field ablation (PFA) or radiofrequency (RF) ablation. The delivery of ablation therapy involves the use of a set of components that requires a reliable electrical pathway for the two-way transmission of electrical signals. These components include: an energy source in the form of pulsed or continuous wave signals such as a pulsed electric field or pulsed RF generator, an ablation delivery catheter that applies PFA or pulsed RF energy to intended endocardial locations in the heart; a catheter electrode distribution system (CEDS); and a set of interconnecting cables.
The CEDS performs the signal adjudication task similar to that of a centralized telephone system in that it prevents mutual interference due to the co-mingling of high energy ablation and very low-energy patient-borne signals. In the downstream case, ablation energy is intended to travel from equipment to the patient, whereas signals that originate at the intracardiac catheter electrodes travel to operating room monitoring equipment in the upstream case. These upstream signals include contact sensing and lesion assessment impedance, navigation, electrode thermocouple signals, and electrogram (EGM) signals.
A second function of the CEDS is to adjudicate patient return electrode (PRE) connections. The PRE is an electrical large area grounding connection to the body generally used when unipolar energy is delivered from an intracardiac catheter with a small electrode surface area relative to the surface area of the PRE. It normally consists of an electrically conductive patch applied to a posterior location such as the patient's lower back. For example, some equipment may require a PRE connection, whereas other items may not or should not. In the case of contact sensing and lesion assessment, a monitoring instrument may require a unipolar or PRE path to render information regarding catheter electrode contact and lesion quality. On the one hand, PFA or pulsed RF bipolar ablation energy should not have a patient reference connection other than the two bipolar connections in the intracardiac treatment volume, whereas unipolar PFA or pulsed RF ablation energy requires a PRE to return treatment energy back to the generator. Therefore, the CEDS is required to “make” PRE contact during sensing and then “break” PRE contact during bipolar PFA or bipolar pulsed RF ablation.
Further, PFA and pulsed RF each involve the use of high energy in the form of current, voltage, or combinations thereof. As such, the delivery pathway may be vulnerable to degradation and eventual failure. The most likely pathway failure is one that occurs in the catheter, primarily because of the failure of very small-gauge wires within the catheter shaft or failure of the insulation on those wires. The diameter of the catheter shaft is severely constrained by the catheter electrical therapy delivery lumen, which places a limit on the size and quantity of the wires that may be used. During PFA or pulsed RF treatment delivery, the very small-gauge wires are vulnerable to heating and arcing. While a properly designed catheter used in a routine cardiac ablation procedure can be expected to provide nominal performance, a procedure requiring significantly longer time with commensurately greater manipulation may cause the catheter to degrade. Without specific information as to the energy delivery integrity of the pathway, the physician performing a lengthened operation does not know the true condition of the catheter. Thus, the user must either choose to continue delivery treatment energy with a possibly degraded catheter, or decide that the catheter should be exchanged to ensure integrity, which essentially renders the original catheter defective. The second option results in an operation with increased time and expense, as well as increased patient risk. If the user could know specifically the limitations of the potentially degraded or damaged catheter, he or she could proceed and complete the operation and avoid exchange costs and patient risk altogether.
Other than the catheter, other pathway locations may be degraded or damaged. For example, an interconnecting cable may become loose or damaged. It is also possible that the generator delivery section may be degraded or damaged. Another example of failure may occur within the CEDS: a relay used to direct energy may be degraded or damaged (inadvertently latched shut or stuck open). In all of these cases, patient therapy is degraded or ineffective. Worse yet, some of these conditions may pose additional hazards to the patient.
Some embodiments advantageously provide methods and systems for confirming safe delivery of treatment energy to a patient by identifying a presence of a fault in an energy delivery pathway and identifying a location of the fault within the device. The system may include a processing unit configured to calculate blood impedances external to the device based on known impedance characteristics of the device, and then to calculate impedances within the device during energy delivery based on the calculated blood impedances. The processing unit may prevent the delivery of energy in an energy delivery pathway that is determined to be compromised. The processing unit may also be configured to compare times for two different frequencies to travel a predetermined distance, the difference in the times corresponding to a location of a fault within the energy delivery pathway.
In one embodiment, a system for assessing integrity of an energy delivery pathway may include an energy generator including a processing unit; an electrode distribution system in communication with the energy generator; an impedance measuring device in communication with the electrode distribution system; a medical device in communication with the electrode distribution system including an elongate body having a proximal portion, a distal portion, and a lumen extending between the proximal portion and the distal portion, a treatment element at the distal portion having at least one electrode, and at least one electrode wire, each of the at least one electrode being connected to one of the at least one electrode wire, the energy delivery pathway including at least a part of each of the at least one electrode wire, the energy generator being configured to deliver a first current at a first frequency and a second current and a second frequency to the at least one electrode, the impedance measuring device being configured to: before a delivery of treatment energy from the energy generator, identify a first wire impedance within the device elongate body, a second wire impedance within the device elongate body, and a first shunt admittance within the device elongate body; during the delivery of the first current at the first frequency and the second current at the second frequency, calculate a first blood impedance external to the device elongate body, a second blood impedance external to the device elongate body, and a blood admittance external to the device elongate body based on the determined first wire impedance within the elongate body, the determined second wire impedance within the device elongate body, and the first shunt admittance within the elongate body; during the delivery of the first current at the first frequency and the second current at the second frequency, calculate a third wire impedance within the device elongate body, a fourth wire impedance within the device elongate body, and a second shunt admittance within the device elongate body based on the first blood impedance external to the device elongate body, the second blood impedance external to the device elongate body, and the blood admittance external to the device elongate body; and at least one of: compare the calculated third wire impedance within the device elongate body and the calculated fourth wire impedance within the device elongate body to determine if a fault in the energy delivery pathway exists; and compare the second shunt admittance within the device elongate body to a threshold admittance value to determine if a fault in the energy pathway exists.
In one embodiment, the energy generator may be configured to deliver ablation energy to the at least one electrode, the processing unit being further configured to prevent delivery of the ablation energy to at least one of the at least one electrode when the processing unit determines a fault in the energy delivery pathway exists.
In one aspect of the embodiment, the impedance measuring device may be configured to render a real portion and an imaginary portion of a complex impedance measurement.
In one aspect of the embodiment, the processing unit may calculate the first blood impedance external to the device elongate body, the second blood impedance external to the device elongate body, and the blood admittance external to the device elongate body by: applying a first condition, i1≠0, i2≠0, to the equations:
and applying a second condition, i′1≠0, i′2=0, to the equations:
In one aspect of the embodiment, the impedance measuring device may calculate the third wire impedance within the device elongate body, the fourth wire impedance within the device elongate body, and the second shunt admittance within the device elongate body by: applying a first condition, i1≠0, i2≠0, to the equations:
and applying a second condition, i′1≠0, i′2=0, to the equations:
In one embodiment, a system for determining a location within a medical device of a fault in an energy delivery pathway may include an energy generator having a processing unit (for example, a PFA or phased RF ablation energy generator); an electrode distribution system including a processing unit and a complex impedance measuring device, the electrode distribution system being in communication with the energy generator, the complex impedance measuring device having a radiofrequency (RF) generator and being configured to render a real portion, r, and an imaginary portion, jx, of an impedance measurement; a medical device in communication with the electrode distribution system including an elongate body having a proximal portion, a distal portion, and a lumen extending between the proximal portion and the distal portion, a treatment element at the distal portion having at least one electrode, and at least one electrode wire, each of the at least one electrode being connected to one of the at least one electrode wire, the energy delivery pathway including at least a part of each of the at least one electrode wire and having a forward portion and a rearward portion, the radiofrequency generator of the complex impedance measuring device being configured to deliver a first test signal along each of the forward portion and the rearward portion of the energy delivery pathway at a first frequency and a second test signal along each of the forward portion and the rearward portion of the energy delivery pathway at a second frequency, the complex impedance measuring device and the processing unit being configured to: calculate a first complex impedance rendered at the first frequency at a known reference point inside the catheter electrode distribution system but representative of incident and reflected waves in each of the forward and rearward portions of the energy delivery pathway propagating to and returning from the tissue load presented to the catheter as well as incident and reflected waves in the rearward portion of the energy delivery pathway propagating to and returning the energy generator, the incident and reflected waves being perturbed in magnitude and phase by potential defects along the forward and rearward portions of the energy delivery pathway, such as opens or shorts; calculate a second complex impedance rendered at the second frequency at the known reference point inside the catheter electrode distribution system but representative of incident and reflected waves in each of the forward and rearward portions of the energy delivery pathway propagating to and returning from the tissue load presented to the catheter as well as incident and reflected waves in the rearward portion of the energy delivery pathway propagating to and returning the energy generator, the incident and reflected waves being perturbed in magnitude and phase by potential defects along the forward and rearward portions of the energy delivery pathway, such as opens or shorts; and identify a location of a fault in the energy delivery pathway within the system based on the real and imaginary components of each of the first and second complex impedances rendered by the complex impedance measuring device.
In one aspect of the embodiment, the first frequency may be approximately 100 MHz and the second frequency may be approximately 65 MHz
In one aspect of the embodiment, the impedance measuring device may be configured to identify the location of the fault in the energy delivery pathway by: comparing the real and imaginary components of the first complex impedance to threshold real and imaginary components; and comparing the real and imaginary components of the second complex impedance to the threshold real and imaginary components. In one aspect of the embodiment, the impedance measuring device may be further configured to minimize the root sum square error between the threshold real and imaginary components, the real and imaginary components of the first complex impedance, and the real and imaginary components of the second complex impedance.
In one aspect of the embodiment, the threshold real and imaginary components may include: a threshold real component for a first fault type; a threshold real component for the second fault type; a threshold imaginary component for a second fault type; and a threshold real component for the second fault type. In one aspect of the embodiment, the threshold real and imaginary components may be stored in the processing unit as a look-up table.
In one embodiment, a method of determining a fault type and a fault location within a medical device may include: measuring a first complex impedance at a first frequency; measuring a second complex impedance at a second frequency; determining a first component and a second component of the first complex impedance; determining a first component and a second component of the first complex impedance; comparing the first component and the second component of each of the first and second impedances to a reference first component over distance and a reference second component over distance; and determining a distance from a proximal end of the medical device based on the comparison, the distance from the proximal end of the medical device being the fault location.
In one aspect of the embodiment, the method may further include: comparing the first component and the second component of each of the first and second impedances to a reference first component over distance for a first fault type, a reference second component over distance for the first fault type, a reference first component over distance for a second fault type, and a reference second component over distance for the second fault type; and determining whether the fault is the first fault type or the second fault type based on the comparison.
A more complete understanding of embodiments described herein, and the attendant advantages and features thereof, will be more readily understood by reference to the following detailed description when considered in conjunction with the accompanying drawings wherein:
Before describing in detail exemplary embodiments, it is noted that the embodiments reside primarily in combinations of apparatus components and processing steps related to the safe delivery of treatment energy to a patient. Accordingly, the system and method components have been represented where appropriate by conventional symbols in the drawings, showing only those specific details that are pertinent to understanding the embodiments of the present disclosure so as not to obscure the disclosure with details that will be readily apparent to those of ordinary skill in the art having the benefit of the description herein.
As used herein, relational terms, such as “first” and “second,” “top” and “bottom,” and the like, may be used solely to distinguish one entity or element from another entity or element without necessarily requiring or implying any physical or logical relationship or order between such entities or elements.
Referring now to
The medical device 12 may be a treatment device, and may optionally include mapping functionality. The medical device 12 may include an elongate body 22 passable through a patient's vasculature and/or proximate to a tissue region for diagnosis or treatment. For example, the device 12 may be a catheter that is deliverable to the tissue region via a sheath or intravascular introducer (not shown). The elongate body 22 may define a proximal portion 26, a distal portion 28, and a longitudinal axis 30, and may further include one or more lumens 32 disposed within the elongate body 22 thereby providing mechanical, electrical, and/or fluid communication between the elongate body proximal portion 26 and the elongate distal portion 28.
The medical device 12 may further include one or more treatment elements 34 at, coupled to, or on the elongate body distal portion 28 for energetic, therapeutic, and/or investigatory interaction between the medical device 12 and a treatment site or region. As a non-limiting example, the device 12 may include a treatment element 34, such as that shown in
The plurality of electrodes 38 may also perform diagnostic functions, such as collection of intracardiac electrograms (EGM) and/or monophasic action potentials (MAPs) as well as performing selective pacing of intracardiac sites for diagnostic purposes. Measured signals may be transferred from the catheter electrode energy distribution system (CEDS) 16 to a recording system input box 40, which may be included in or integrated with the generator 14. The plurality of electrodes 38 may also monitor the proximity to target tissues and quality of contact with such tissues using impedance based measurements with connections to the CEDS 16. The CEDS 16 may include high speed relays to disconnect/reconnected specific electrodes 38 from the generator 14 during an energy delivery procedure.
Although not shown, the system 10 may include one or more sensors to monitor the operating parameters throughout the system, in addition to monitoring, recording or otherwise conveying measurements or conditions within the medical device 12 or the ambient environment at the distal portion of the medical device 12. The sensor(s) may be in communication with the generator 14 and/or the CEDS 16 for initiating or triggering one or more alerts or therapeutic delivery modifications during operation of the medical device 12.
The medical device 12 may include a handle 42 coupled to the elongate body proximal portion 26. The handle 42 may include circuitry for identification and/or use in controlling of the medical device 12 or another component of the system. Additionally, the handle 42 may also include connectors that are mateable to the generator 14 and/or the CEDS 16 to establish communication between the medical device 12 and the generator 14 and/or the CEDS 16. The handle 42 may also include one or more actuation or control features that allow a user to control, deflect, steer, or otherwise manipulate a distal portion of the medical device 12 from the proximal portion of the medical device 12.
The generator 14 may include processing circuitry including one or more processing units 44 in communication with one or more controllers and/or memories containing software modules containing instructions or algorithms to provide for the automated operation and performance of the features, sequences, calculations, or procedures described herein and/or required for a given medical procedure. Specifically, each processing unit 44 may have processing circuitry that includes a memory and processor, with the processing circuitry being configured to receive data from the treatment device 12, process data, and to communicate data to a navigation system (not shown) and/or directly the user. As a non-limiting example, the generator 14 may be a GENius® Generator (Medtronic, Inc.) that includes one or more displays 46, user input devices, controllers, data storage units, or the like. Additionally, although the CEDS 16 is shown as being external to the generator 14, it alternatively may be integrated with the generator 14.
The system 10 may further include a plurality of surface ECG electrodes 48 in communication with the generator 14 through the CEDS 16. When the surface electrodes 48 are applied to the skin of a patient, they may be used, for example, to monitor the patient's cardiac activity to determine pulse train delivery timing at the desired portion of the cardiac cycle and/or for navigation and location of the device 12 within the patient. In addition to monitoring, recording, or otherwise conveying measurements or conditions within the medical device 12 or the ambient environment at the distal portion 28 of the medical device 12, additional measurements may be made through connections to the multi-electrode device, such as temperature, electrode-tissue interface impedance, delivered charge, current, power, voltage, work, or the like in the generator 14 and/or the device 12. The surface ECG electrodes 26 may be in communication with the generator 14 for initiating or triggering one or more alerts or therapeutic deliveries during operation of the medical device 12. Additional patient return electrode (PRE) patches (not shown) may be used to evaluate the desired bipolar electrical path impedance, as well as monitor and alert the operator upon detection of undesired and/or unsafe conditions.
The generator 14 may provide electrical pulses to the medical device 12 to perform an electroporation procedure to cardiac tissue or other tissues within the patient's body, such as renal tissue, airway tissue, and organs or tissue within the thoracic or abdominal cavities including the cardiac space. Specifically, generator 14 may be configured and programmed to deliver pulsed, high-voltage electric fields appropriate for achieving desired pulsed, high-voltage ablation (referred to as “pulsed field ablation” or “pulsed electric field ablation”) and/or pulsed radiofrequency ablation. As a point of reference, the pulsed, high-voltage, non-radiofrequency, ablation effects of the present disclosure are distinguishable from DC current ablation, as well as thermally-induced ablation attendant with conventional RF techniques. The pulsed-field energy may be sufficient to induce cell death for purposes of completely blocking an aberrant conductive pathway along or through cardiac tissue, destroying the ability of the so-ablated cardiac tissue to propagate or conduct cardiac depolarization waveforms and associated electrical signals. Additionally or alternatively, the generator 14 may be configured and programmed to deliver RF and/or pulsed RF energy appropriate for achieving tissue ablation.
The CEDS 16 may be located adjacent to the patient and may be connected to an implanted device (that is, a device that is located within the patient). Cables of various lengths, for example, between 3 and 10 feet in length, may interconnect the generator 14, CEDS 16, and the device 12. Electrical pathways or transmission lines may exist between the CEDS 16 and device electrodes 38 that present impedances that are unique and discernible depending on defects to the device 12. A complex impedance measuring device 52 (which may be referred to as a “Z-meter”) may be located remotely from the device 12 and may be configured to resolve various electrode combinations via the delivery pathway at frequencies in the range of between approximately 1 kHz and approximately 1 MHz. The impedance measuring device 52 may be configured to render a real portion, r, and an imaginary portion, jx, of a complex impedance measurement. The complex impedance measuring device 52 may include an extremely low-level (nanowatt) RF energy generator 53 for delivering test signals at different frequencies along a forward (that is, toward the device 12) and rearward (that is, toward the PFA or pulsed RF generator 14) portion of the energy delivery pathway. The complex impedance measuring device 52 may be in communication with the CEDS 16, or may be a part of the CEDS 16, and may receive signals from the treatment element 34 through the CEDS 16. The impedance measuring device 52 may iteratively measure various electrode combinations such that it can fill a solution matrix with a number of “knowns” sufficient to solve the number of unknowns, such as the device's intrinsic series impedance and shunt admittances. For example, a set of unipolar impedances Zu,1, Zu,2, . . . Zu,n and bipolar admittances Yb,1-2, Yb,2-3, . . . Yb,n-1,n may be accurately determined for blood or tissue in situ, where magnitude and phase impedance and admittance values are used to discern the catheter's condition.
Referring now to
The process may begin by applying two complex currents i1(jω) and i2(jω) (which may be later abbreviated as i1 and i2) at frequencies of interest via a first voltage source 64, V1(jω), and a second voltage source 66, V2(jω), located within the generator 14. Three initial equations may be used to determine impedance at the device-to-blood (or device-to-tissue), shown below. The values i1, i2, R1, R2, V1, and V2 are known. Additionally, as discussed immediately above, values Zl,1, Zl,2, and Yl,1-2 are known. The value Yl,1-2 represents the admittance introduced into the impedance measuring device 52. There initially may be four unknown values: ib, Zu,1, Zu,2, and Yb,1-2. The value ib represents bipolar current flowing through a loop between two device electrodes 38 via tissue and/or blood. The values Zu,1 and Zu,2 represent the unipolar impedances of the two electrodes 38 and Yb,1-2 is the bipolar admittance between the two electrodes 38 introduced into the device 12 (including the elongate body 22 and device cables). To determine these unknown values, a first condition may be applied by the processing unit 44: i1≠0, i2≠0. The three initial equations are:
where V1 represents the known voltage of the first voltage source 64, V2 is the known voltage of the second voltage source 66, R1 represents a known resistance value of the first wire 56, R2 represents a known resistance value of the second wire 58, Zl,1 represents the known series impedance of the first wire 56, Zl,2 represents the known series impedance of the second wire 58, Zu,1 represents an unknown first blood impedance, Zu,2 represents an unknown second blood impedance, ib represents bipolar current flowing through a loop between two device electrodes 38 via tissue and/or blood. Primed variables (for example, i′1) represent the same electrical measurements as their non-primed counterparts, but are generated using a second measurement condition, and are included to balance the unknown values with the same number of equations. Further, the admittance term, Ysh, is the parallel combination of leakage or conductance between the first 56 and second 58 wires and the blood admittance between the first and second electrodes 38, or:
Ysh=Yl,1-2+Yb,1-2 (4)
Equations (1), (2), and (3) contain four unknown variables. To resolve the unknowns, at least one more orthogonal equation is necessary. Therefore, a second condition may be applied by the processing unit 44 as: i′1≠0, i′2=0. Since the system shown schematically in
where V′1 represents the known voltage of the first voltage source 64, i′1 represents the first complex current, R1 is a known resistance value of the first wire 56, Zl,1 is the known series impedance of the first wire 56, Zu,1 is the unknown first blood impedance, Zu,2 is the unknown second blood impedance, i′b represents bipolar current flowing through a loop between two device electrodes 38 via tissue and/or blood, and Ysh is the parallel combination of the unknown leakage or conductance between the first 56 and second 58 electrode wires, Yl,1-2, and the known blood admittance between the first and second electrodes 38, Yb,1-2.
The resulting set includes five equations and five unknown values for which a numerical solution can be obtained at each frequency component or current using one or more algorithms executed by the processing unit 44. Once all the impedance values shown in
Referring to
The resulting set includes give five equations and five unknown values for which a numerical solution can be obtained at each frequency component or current using one or more algorithms executed by the processing unit 44. Once all the impedance values shown in
Slight changes to the lumen wire 56, 58 impedance values are normal and may not be indicative of a degraded device 12. On the other hand, significant changes, such as greatly increased admittance value (as compared, for example, to a predetermined threshold admittance value), Ysh, between a wire pair may indicate a partial or complete short circuit has occurred. Likewise, a significant increase in the series impedance component, Zl,1 or Zl,2, relative to each other or over a predetermined threshold impedance value may indicate that a wire 56, 58 has overheated with high resistance or has open circuited. As a result, the processing unit 44 is able to verify the pathway signal integrity and prevent ablation energy from being delivered to the damaged portion of the device 12. The generator 14 may then inform the user, such as through the one or more displays 46, to rotate the device 12 to an electrode position with verified signal integrity and continue to deliver ablation energy to the tissue. By continuing to deliver ablation energy with a partially damaged device, the user avoids the time, expense, and patient risks associated with a catheter exchange. In other words, risks associated with energy delivery from the partially damaged device when the device is in the new electrode position recommended by the system are outweighed by the risks associated with device replacement during the procedure.
Referring now to
Although impedance may be used to identify a normal condition or a fault in the form of an open or short, such technique does not identify the specific location of the fault. Frequency domain reflectometry, on the other hand, does provide information about the location of the fault within the device, and may be used instead of temperature readings from thermocouples to identify that location. Using this information, a user may quickly remedy the problem causing the fault during a procedure. As a non-limiting example, a fault location is represented with an “X” in
where {right arrow over (k)}g is along a path of the wire, or longitudinal {right arrow over (a)}z direction, and is inverse to the guide wavelength of the propagating mode of energy.
For the case of propagating waves inside a device lumen, there are two important properties of the wave vector {right arrow over (k)}g. First, {right arrow over (k)}g is strongly related to the catheter construction and design; therefore, it may be considered to be an a priori performance constant. Second, the fact that a wave propagates through a uniform cross section inside a device lumen as it traverses from the proximal to distal end implies that {right arrow over (k)}g is constant along the length of the device. Therefore, the wave will propagate predictably according to the design and construction of the catheter and also to the laws and relations governing radio frequency (RF) transmission line theory. Consider the system shown in
where the 2×1 matrix [R] is the product of three 2×2 matrix elements and the 2×1 tested pathway transmission equation with the blood admittance termination vector:
The individual section matrices are given as:
(a) the 2×2 transmission line matrix [xmsn1] preceding the fault is expressed as:
(b) the 2×2 matrix [zf] is the presumptive series fault matrix:
or shunt fault matrix:
(c) the 2×2 transmission line matrix [xmsn2] following the fault is expressed as:
(d) and the electrode impedance in blood is given as:
where:
When describing a transmission line, the wave propagation vector may be expressed as a complex exponential consisting of a loss, a, and wavelength term, β:
kg=α+jβ (16)
The loss term, α, is given in terms of nepers per unit length and usually derived from decibel loss per some arbitrary length:
and the wavelength term is given as:
where ko is the free-space wave vector, and vp is the velocity of propagation in the medium, in this case, a pair of wares from a larger group located inside a catheter lumen.
Therefore, given a priori knowledge of the guide wave properties of the lumen 32, it is possible to accurately determine the distance to a reflection caused by an open or short circuit by measuring the impedance from the proximal side, zin. To perform the measurement, the complex impedance measurement device 52 applies a very low power sin wave at an evaluation frequency (50<f<100 MHz) and measures a complex impedance in the form of real and imaginary components, or:
z(jω)=r+jx (19)
By using nanowatt power and a spectrally efficient sin wave source instead of a broad spectrum unit step pulse that is used in time domain reflectometry, this method requires far less power, typically much less than 10 μA as required by regulatory authority, which limits patient current to safe levels.
Assuming that the fault is either in the form of a partial or complete open, or a partial or complete short, both the fault impedance magnitude and location are discernible.
While the nominal catheter's real and imaginary impedance remains relatively constant versus d1, both real and imaginary impedance components of the faulty catheter differ considerably from the nominal catheter's impedance. For example, if the real part of the measured impedance of the faulty catheter, Re{Zmeas,F=65M}, approximately equals 3 Ohms at 65 MHz, and the imaginary component of the faulty catheter, Im{Zmeas,F=65M}, approximately equals −150 Ohms at 65 MHz, then the fault location is nearly one foot from the proximal end, and the impairment is an open or wire break. Another otherwise normal wire pair may render a nearly constant real impedance of 100 Ohms, with a negligible reactance, or Im{Zmeas}˜0 Ohms.
Yet, unless impedance is tested at a second frequency, a single frequency result may leave a fault ambiguous as to its type (that is, short or open) and location. The user would know only that they have an “open” fault at location “A,” or a “shorted” fault at location “B,” for example. The following method may be used to remove this ambiguity and provide for a single-fault solution. Assume that an “open” or series fault exists one foot from the proximal end of the elongate body. According to the 65 MHz graph in
The generator processing unit 44 may include a microcontroller with a set of coded instructions for executing the algorithm for this method. The microcontroller may first configure the generator relays and signal paths to present the desired pathway, that pathway being forward from the electrode distribution system to the medical device or catheter 12, or a rearward pathway back to the PFA or RF ablation energy generator 14. Next, the microcontroller may instruct the impedance measuring device 52 to perform an impedance measurement of the selected signal path at two frequencies (for example, between 50 and 100 MHz). The microcontroller may then compare the following four values to a pre-tabulated list of open and short impedances for the first and second frequency and given pathway: (1) the proximal end real impedance component rendered at the first frequency; (2) the proximal end imaginary impedance component rendered at the first frequency; (3) the corresponding proximal end real impedance component rendered at the second frequency; and (4) the corresponding proximal end imaginary impedance component rendered at the second frequency. Then, by correlation by minimizing the root sum square error between a nominal table set of the four impedances and the measured data, the microcontroller may identify the type of fault and its location.
While the process described above was discussed regarding an exemplary catheter with an “open” or “shorted” fault, the same process may be applied to the system 10 as a whole, rather than just the device 12 used with the system. For example, a rearward pathway may be established between the CEDS 16, the interconnecting cable between the CEDS 16 and the PFA or RF generator 14, and continuing inside the generator 14 up to a half bridge system 80 (referred to in
The nominal input impedance from the perspective of the impedance meter in
The additional terms in Equation (20) represent discontinuities or radio wave reflection locations at the very high frequency (VHF) test frequencies, typically between 50 MHz and 100 MHz (50 MHz<F<100 MHz). For example, a connector may increase series inductance relative to the cable wire pairs and cause a reflection; therefore, a term and its location should be part of the transmission pathway. Another example is the presence of a large patient protection vacuum relay between the H bridge delivery insulated gate bipolar transistors (IGBTs) and the generator-to-CEDS therapy connection cable. The large relays, although they would not cause a reflection at the audio frequency range PFA treatment energy (that is, they are invisible from a reflectometry standpoint at this frequency), they become more significant with the use of VHF where they would cause a reflection in the tested pathway. However, these discontinuities are readily discoverable in the nominal design as lumped series or shunt impedances and thus are readily managed as terms added to the pathway Equation (20). The terms in Equation (20) are known a priori for a nominal system.
By adding arbitrary series or shunt faults to Equation (20), impedance graphs can be generated similar to those shown in
To gain confidence that the system 10 is functioning properly and safe to use, the user may perform a pre- (or post-) operational functional test to confirm that all delivery pathways are in nominal operating condition. Prior to beginning an operation, pathway impairments or faults may occur, such as saline or blood entering the end of the generator-to-CEDS cable and coating the high voltage delivery connections, or by a bent or missing connector pin, or a broken wire in a cable. If any of the aforementioned faults exist, then upon the first delivery of treatment energy, an arc would ensue that could ruin additional pathway components (other than the original fault) such as a cable, connector or generator electronic components. Therefore, a pre-operational test would be useful in identifying such a fault, which in the case of fluid contamination inside a connector, could be easily cleaned and dried. Such a test or check could be applied posthaste of a delivery in which case the generator's fault system identifies and informs the user of inappropriate treatment energy in the form of excessive or insufficient current, charge, or power. An example would be the microprocessor's identification of a fault such as a “short” in a catheter extension cable. By providing the ability to identify the specific location, and thus the specific faulty item, the microprocessor can communicate this information to the user and recommend replacement of the catheter extension cable, rather than providing an ambiguous result that one of three (or more) faults exist: a faulty catheter extension cable, a faulty catheter, or a faulty CEDS. The consequences of the last two failures are serious and pose additional patient risk: a suspected faulty catheter requires explant and replacement in order to complete the PFA treatment procedure; a damaged CEDS could force the user to abort the procedure altogether. Upon the user's replacement of the catheter extension cable, the system may perform a subsequent pathway check to confirm the proper functioning state of the system. The advantage to the customer is a rapid method of providing a specific remedy to an equipment problem, thereby minimizing the user's time and labor required to perform an on-site repair, which in the case of an in-progress intracardiac operation, would be imperative.
Further, not only can the RF pulses be differentiated by frequency, but they may also be differentiated by delivery patterns. In the case of a multi-conductor lead, similar sets of pulses may be applied to all electrodes 38. For example, for a device having nine electrodes (E1-E9), energy may be delivered to the electrodes 38 in the following pattern: E1 to E2, E2 to E3, E3 to E4, E4 to E5, E5 to E6, E6 to E7, E7 to E8, and E8 to E9. Faults may be identified by examining the various electrode combinations.
Non-limiting examples of informational displays are shown in
Exemplary data is shown in
It will be appreciated by persons skilled in the art that the present embodiments are not limited to what has been particularly shown and described herein above. In addition, unless mention was made above to the contrary, it should be noted that all of the accompanying drawings are not to scale. A variety of modifications and variations are possible in light of the above teachings.
Stewart, Mark T., Zhang, Qin, Condie, Catherine R., Fraasch, Steven J., Rehberger, Trenton J.
Patent | Priority | Assignee | Title |
Patent | Priority | Assignee | Title |
4416276, | Oct 26 1981 | Sherwood Services AG | Adaptive, return electrode monitoring system |
5231987, | Apr 10 1992 | Random Technologies, Inc.; RANDOM TECHNOLOGIES, INC A CORP OF INDIANA | Time domain reflectometer-integrity testing system and method for implantable electrode |
5361776, | Aug 06 1993 | Pacesetter, Inc | Time domain reflectometer impedance sensor method of use and implantable cardiac stimulator using same |
6796980, | Nov 21 2001 | Cardiac Pacemakers, Inc. | System and method for validating and troubleshooting ablation system set-up |
7070595, | Dec 14 1998 | Medwaves, Inc. | Radio-frequency based catheter system and method for ablating biological tissues |
7966137, | Oct 03 2005 | WIRESCAN AS | Line resonance analysis system |
8352033, | Oct 15 2007 | Apparatus and methods for measuring defibrillation lead impedance via a high magnitude, short duration current pulse | |
8700156, | Oct 15 2007 | Lamda Nu, LLC | High accuracy painless method for measuring defibrillation lead impedance |
20110071516, | |||
20120316454, | |||
20150005862, | |||
20160310204, | |||
EP2301462, | |||
KR101570506, | |||
WO2016160448, |
Executed on | Assignor | Assignee | Conveyance | Frame | Reel | Doc |
Feb 13 2017 | FRAASCH, STEVEN J | Medtronic, Inc | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 041251 | /0816 | |
Feb 13 2017 | CONDIE, CATHERINE R | Medtronic, Inc | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 041251 | /0816 | |
Feb 13 2017 | REHBERGER, TRENTON J | Medtronic, Inc | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 041251 | /0816 | |
Feb 13 2017 | STEWART, MARK T | Medtronic, Inc | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 041251 | /0816 | |
Feb 13 2017 | ZHANG, QIN | Medtronic, Inc | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 041251 | /0816 | |
Feb 14 2017 | Medtronic, Inc. | (assignment on the face of the patent) | / |
Date | Maintenance Fee Events |
Jul 20 2023 | M1551: Payment of Maintenance Fee, 4th Year, Large Entity. |
Date | Maintenance Schedule |
Feb 11 2023 | 4 years fee payment window open |
Aug 11 2023 | 6 months grace period start (w surcharge) |
Feb 11 2024 | patent expiry (for year 4) |
Feb 11 2026 | 2 years to revive unintentionally abandoned end. (for year 4) |
Feb 11 2027 | 8 years fee payment window open |
Aug 11 2027 | 6 months grace period start (w surcharge) |
Feb 11 2028 | patent expiry (for year 8) |
Feb 11 2030 | 2 years to revive unintentionally abandoned end. (for year 8) |
Feb 11 2031 | 12 years fee payment window open |
Aug 11 2031 | 6 months grace period start (w surcharge) |
Feb 11 2032 | patent expiry (for year 12) |
Feb 11 2034 | 2 years to revive unintentionally abandoned end. (for year 12) |